The Newsfront

Neurofront Therapeutics is a clinical-stage biotechnology company dedicated to the development and commercialization of innovative therapies for neurological and psychiatric disorders. The company primarily focuses on the Greater China and Asian markets, utilizing a strategy that combines in-licensing late-stage assets with internal research and development. Its lead program, NRT-001 (eptinezumab), is a monoclonal antibody targeting CGRP for the treatment of migraine, licensed from Lundbeck. Neurofront is supported by prominent life science investors, including OrbiMed and Morningside Venture Capital, and aims to address significant unmet medical needs in the central nervous system therapeutic area.